Format

Send to

Choose Destination
J Nucl Med. 2017 Oct;58(10):1553-1559. doi: 10.2967/jnumed.117.189944. Epub 2017 Jul 7.

Pretargeted Imaging and Therapy.

Author information

1
Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
2
Department of Chemistry, Hunter College of the City University of New York, New York, New York.
3
PhD Program in Chemistry, Graduate Center of the City University of New York, New York, New York; and.
4
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
5
Department of Chemistry, Hunter College of the City University of New York, New York, New York bz102@hunter.cuny.edu.

Abstract

In vivo pretargeting stands as a promising approach to harnessing the exquisite tumor-targeting properties of antibodies for nuclear imaging and therapy while simultaneously skirting their pharmacokinetic limitations. The core premise of pretargeting lies in administering the targeting vector and radioisotope separately and having the 2 components combine within the body. In this manner, pretargeting strategies decrease the circulation time of the radioactivity, reduce the uptake of the radionuclide in healthy nontarget tissues, and facilitate the use of short-lived radionuclides that would otherwise be incompatible with antibody-based vectors. In this short review, we seek to provide a brief yet informative survey of the 4 preeminent mechanistic approaches to pretargeting, strategies predicated on streptavidin and biotin, bispecific antibodies, complementary oligonucleotides, and bioorthogonal click chemistry.

KEYWORDS:

biotin; bispecific antibody; click chemistry; multistep targeting; pretargeting; streptavidin

PMID:
28687600
PMCID:
PMC5632733
DOI:
10.2967/jnumed.117.189944
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center